✦ LIBER ✦

A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor

✍ Scribed by M. Y. CHAN; C. P. RUSCONI; J. H. ALEXANDER; R. M. TONKENS; R. A. HARRINGTON; R. C. BECKER

Book ID: 109152490
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 315 KB
Volume: 6
Category: Article
ISSN: 1538-7933
DOI: 10.1111/j.1538-7836.2008.02932.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, pharmacodynamics, and safety o

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies

✍ Nemanja Damjanov; Robert S. Kauffman; George T. Spencer-Green 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

Efficacy and safety of bifeprunox in pat

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study

✍ Daniel E. Casey; Earl E. Sands; Jens Heisterberg; Hwa-Ming Yang 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 291 KB

Safety and Efficacy of Dietary Agmatine

Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial

✍ Ory Keynan; Yigal Mirovsky; Samuel Dekel; Varda H. Gilad; Gad M. Gilad 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

MLN3897 plus methotrexate in patients wi

MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study

✍ Clarissa E. Vergunst; Danielle M. Gerlag; Lisa von Moltke; Michael Karol; Tim Wy 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 3 views

## Abstract ## Objective To assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of the CC chemokine receptor CCR1 antagonist MLN3897 in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX). ## Methods In this phase IIa, proof‐of‐concept study, patients meeting the

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ P. P. Tak; P. J. Mease; M. C. Genovese; J. Kremer; B. Haraoui; Y. Tanaka; C. O. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views